Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL840714 | 0.83 | PDE2A (0.38) | TRPV3GRM2PDE2AKDM4EALDH1A1 | |
| SCHEMBL839176 | 0.82 | ALDH1A1 (0.50) | KMT2AMEN1GAATAAR1POLB | |
| SCHEMBL840936 | 0.79 | AVPR1B (0.34) | PDE2AKDM4EALDH1A1LMNA | |
| SCHEMBL840253 | 0.79 | KMT2A (0.46) | KMT2AMEN1GAAGRM2HTR7 | |
| SCHEMBL838762 | 0.78 | ALDH1A1 (0.47) | KDM4EALDH1A1 | |
| SCHEMBL18998097 | 0.71 | MEN1 (0.63) | KMT2AMEN1GAAHTR7POLB | |
| SCHEMBL839362 | 0.70 | ADORA2A (0.36) | TRPV3KMT2AMEN1GRM2ALDH1A1 | |
| SCHEMBL840171 | 0.70 | KDM4E (0.54) | KMT2AMEN1POLBKDM4EALDH1A1 | |
| SCHEMBL839105 | 0.70 | CYP2A13 (0.47) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL840943 | 0.69 | HDAC4 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373639-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V. Organon (NL) | 2011-10-12 | — | — | EP | disclosed |
| US-20100144724-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V.ORGANON | 2010-06-10 | — | — | US | disclosed |
| WO-2010063666-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V. ORGANON (NL) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144724-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | OPRD1, CNR1, CNR2 | TRPV3 627/4885KMT2A 1921/4885MEN1 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.